Among NSCLC patients with PD‐L1 expression in more than 50% of tumour cells, treatment with Pembrolizumab, which targets PD‐1, leads to a superior progression‐free and overall survival compared to platinum‐doublet chemotherapy in the first‐line setting.4 This evidence concerns the gene PDCD1 and neoplasm.